Esperion Therapeutics (ESPR) Misses Q1 EPS by 12c

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.79), $0.12 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $24.3 million versus the consensus estimate of $21.86 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• Nolan’s ’The Odyssey’ eyes $200M global debut, benefiting IMAX and theater stocks
• Spirit Blockchain Capital reports AGM results and board changes